AxoGen, Inc. (NASDAQ:AXGN) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC lessened its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 14.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 127,076 shares of the medical equipment provider’s stock after selling 21,370 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.29% of AxoGen worth $2,094,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Divisadero Street Capital Management LP grew its stake in AxoGen by 2.7% in the 4th quarter. Divisadero Street Capital Management LP now owns 26,972 shares of the medical equipment provider’s stock valued at $444,000 after acquiring an additional 700 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of AxoGen by 4.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,128 shares of the medical equipment provider’s stock valued at $398,000 after purchasing an additional 926 shares during the period. Principal Financial Group Inc. increased its stake in shares of AxoGen by 8.3% during the fourth quarter. Principal Financial Group Inc. now owns 16,000 shares of the medical equipment provider’s stock worth $264,000 after purchasing an additional 1,228 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of AxoGen by 2.7% in the fourth quarter. Rhumbline Advisers now owns 58,232 shares of the medical equipment provider’s stock worth $960,000 after acquiring an additional 1,521 shares during the last quarter. Finally, R Squared Ltd purchased a new stake in shares of AxoGen during the fourth quarter worth $30,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Stock Performance

AxoGen stock opened at $10.97 on Tuesday. The firm has a 50 day simple moving average of $14.64 and a 200-day simple moving average of $16.07. The stock has a market cap of $499.62 million, a price-to-earnings ratio of -34.28 and a beta of 1.19. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. AxoGen, Inc. has a 1-year low of $6.57 and a 1-year high of $21.00.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AXGN. Canaccord Genuity Group decreased their target price on shares of AxoGen from $26.00 to $24.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $24.00 price target on shares of AxoGen in a report on Wednesday, March 5th. Finally, Lake Street Capital started coverage on AxoGen in a research note on Monday, March 17th. They set a “buy” rating and a $30.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, AxoGen has an average rating of “Buy” and a consensus target price of $22.20.

Insider Buying and Selling at AxoGen

In other news, insider Erick Wayne Devinney sold 15,111 shares of the stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total value of $264,442.50. Following the sale, the insider now directly owns 217,762 shares in the company, valued at approximately $3,810,835. This trade represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph A. Tyndall sold 20,062 shares of AxoGen stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $11.20, for a total value of $224,694.40. Following the completion of the transaction, the director now owns 15,345 shares of the company’s stock, valued at $171,864. The trade was a 56.66% decrease in their position. The disclosure for this sale can be found here. 2.78% of the stock is currently owned by corporate insiders.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.